Celator Pharmaceuticals, Inc.

Phase IIB, multicenter, randomized, open-label trial of CPX-351 (Cytarabine:Daunorubicin) liposome injection versus intensive salvage therapy in adult patients = 60 years old with AML in first relapse following an initial CR > 1 month duratio